• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Early Release: Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA

Mary Wilson

Well-known member
Volume 29, Number 2—February 2023

DOI: 10.3201/eid2902.220817

Dakai Liu[SUP]1[/SUP], Yexiao Cheng[SUP]1[/SUP], Hangyu Zhou, Lulan Wang, Roberto Hurtado Fiel, Yehudah Gruenstein, Jean Jingzi Luo, Vishnu Singh, Eric Konadu, Keither James, Calvin Lui, Pengcheng Gao, Carl Urban, Nishant Prasad, Sorana Segal-Maurer, Esther Wurzberger, Genhong Cheng , Aiping Wu , and William Harry Rodgers

Abstract

The Omicron variant of SARS-CoV-2 has become dominant in most countries and has raised significant global health concerns. As a global commerce center, New York, New York, USA, constantly faces the risk for multiple variant introductions of SARS-CoV-2. To elucidate the introduction and transmission of the Omicron variant in the city of New York, we created a comprehensive genomic and epidemiologic analysis of 392 Omicron virus specimens collected during November 25–December 11, 2021. We found evidence of 4 independent introductions of Omicron subclades, including the Omicron subclade BA.1.1 with defining substitution of R346K in the spike protein. The continuous genetic divergence within each Omicron subclade revealed their local community transmission and co-circulation in New York, including both household and workplace transmissions supported by epidemiologic evidence. Our study highlights the urgent need for enhanced genomic surveillance and effective response planning for better prevention and management of emerging SARS-CoV-2 variants.

https://wwwnc.cdc.gov/eid/article/29/2/22-0817_article
 
Back
Top